GALECTO INC(NASDAQ:GLTO) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GLTO. GLTO was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GLTO as it has an excellent financial health rating, but there are worries on the profitability. GLTO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GLTO has reported negative net income.

GLTO had a negative operating cash flow in the past year.

In the past 5 years GLTO always reported negative net income.

GLTO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of GLTO (-90.58%) is worse than 72.01% of its industry peers.

GLTO has a Return On Equity of -101.14%. This is comparable to the rest of the industry: GLTO outperforms 45.81% of its industry peers.

		Industry Rank	Sector Rank
ROA	-90.58%
ROE	-101.14%
ROIC	N/A

ROA(3y)-75.62%

ROA(5y)-64.3%

ROE(3y)-87.49%

ROE(5y)-74.05%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLTO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLTO has less shares outstanding

Compared to 5 years ago, GLTO has less shares outstanding

GLTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

GLTO has an Altman-Z score of -16.64. This is a bad value and indicates that GLTO is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -16.64, GLTO is doing worse than 84.49% of the companies in the same industry.

GLTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-16.64

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

GLTO has a Current Ratio of 8.68. This indicates that GLTO is financially healthy and has no problem in meeting its short term obligations.

GLTO has a Current ratio of 8.68. This is in the better half of the industry: GLTO outperforms 75.22% of its industry peers.

A Quick Ratio of 8.68 indicates that GLTO has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 8.68, GLTO is in the better half of the industry, outperforming 75.22% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	8.68
Quick Ratio	8.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.44% over the past year.

EPS 1Y (TTM)58.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%54.8%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

GLTO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.54% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y55.54%

EPS Next 2Y27.34%

EPS Next 3Y15.4%

EPS Next 5Y-0.54%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GLTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GLTO's earnings are expected to grow with 15.40% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y27.34%

EPS Next 3Y15.4%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLTO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GALECTO INC

NASDAQ:GLTO (2/21/2025, 8:23:57 PM)

4.51

-0.33 (-6.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-01 2024-11-01/bmo

Earnings (Next)03-06 2025-03-06/amc

Inst Owners13.05%

Inst Owner Change10.44%

Ins Owners3.61%

Ins Owner Change0.1%

Market Cap5.95M

Analysts85.71

Price Target8.16 (80.93%)

Short Float %1.03%

Short Ratio0.7

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)34.58%

Min EPS beat(2)18.96%

Max EPS beat(2)50.2%

EPS beat(4)4

Avg EPS beat(4)36.28%

Min EPS beat(4)18.96%

Max EPS beat(4)52.18%

EPS beat(8)8

Avg EPS beat(8)29.91%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-20%

PT rev (3m)-20%

EPS NQ rev (1m)12.9%

EPS NQ rev (3m)12.9%

EPS NY rev (1m)27.42%

EPS NY rev (3m)27.42%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.28
P/tB	0.28
EV/EBITDA	N/A

EPS(TTM)-18.39

EYN/A

EPS(NY)-13.81

Fwd EYN/A

FCF(TTM)-19.06

FCFYN/A

OCF(TTM)-19.06

OCFYN/A

SpS0

BVpS15.86

TBVpS15.86

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-90.58%
ROE	-101.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-75.62%

ROA(5y)-64.3%

ROE(3y)-87.49%

ROE(5y)-74.05%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.68
Quick Ratio	8.68
Altman-Z	-16.64

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)533.33%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)58.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%54.8%

EPS Next Y55.54%

EPS Next 2Y27.34%

EPS Next 3Y15.4%

EPS Next 5Y-0.54%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y54.26%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-30.35%

EBIT Next 3Y-18.73%

EBIT Next 5YN/A

FCF growth 1Y49.13%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y48.98%

OCF growth 3YN/A

OCF growth 5YN/A

GALECTO INC (GLTO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens